title: Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
authors.affiliation: Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
authors.forename: Guillermo L
authors.initials: GL
authors.lastname: Rivell
authors.forename: Chris Y
authors.initials: CY
authors.lastname: Brunson
authors.forename: Laura
authors.initials: L
authors.lastname: Milligan
authors.forename: Robert K
authors.initials: RK
authors.lastname: Stuart
authors.forename: Luciano J
authors.initials: LJ
authors.lastname: Costa
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006785:Hospitals, University; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000009:adverse effects; D012720:Severity of Illness Index; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D007155:Immunologic Factors; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003520:Cyclophosphamide